[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
May 1997

Middle-Term Evolution of Patients With Advanced Cutaneous T-Cell Lymphoma Treated With High-Dose Recombinant Interleukin-2

Author Affiliations

Hôpital Saint Louis 75475 Paris Cedex 10, France

Arch Dermatol. 1997;133(5):656. doi:10.1001/archderm.1997.03890410120021

In the May 1995 issue of the Archives, we reported1 the efficacy of high-dose recombinant interleukin-2 in the treatment of 7 patients with advanced cutaneous T-cell lymphoma (CTCL). In January 1994, we observed 3 patients with complete remissions and 2 with progressive disease as a result of this treatment. Two patients of the 7 had already died of their lymphomas. In this letter, we report the evolution of the 5 remaining patients as of November 1996.

The 2 patients whose disease was progressive died as a result of their lymphomas (patient 5 in January 1994 and patient 4 in July 1994). Patient 7 relapsed in March

First Page Preview View Large
First page PDF preview
First page PDF preview